{
    "clinical_study": {
        "@rank": "107584", 
        "acronym": "A2NTX", 
        "arm_group": [
            {
                "arm_group_label": "A2NTX", 
                "arm_group_type": "Experimental", 
                "description": "single intramuscular injection of 300 units of A2NTX, a purified low molecular weight (150 kDalton) botulinum toxin preparation of type A2"
            }, 
            {
                "arm_group_label": "BOTOX", 
                "arm_group_type": "Active Comparator", 
                "description": "single intramuscular injection of 300 units of BOTOX\u00ae, a commercially available botulinum toxin preparation of type A1"
            }
        ], 
        "brief_summary": {
            "textblock": "To test the safety and efficacy of a new generation botulinum toxin preparation A2NTX for\n      treating stroke patients with lower limb spasticity.\n\n        -  we study the degree of spasticity in the ankle and knee joints, and walking speed in 30\n           patients with stroke before and after injecting 300 units of BOTOX or A2NTX in a\n           blinded manner as for the patient, the physician, and the examiner.\n\n        -  we also assess the safety of A2NTX and compare it to that of BOTOX."
        }, 
        "brief_title": "Study of a New Generation Botulinum Toxin A2NTX to Treat Spasticity After Stroke", 
        "condition": "Lower Limb Spasticity After Stroke", 
        "condition_browse": {
            "mesh_term": [
                "Muscle Spasticity", 
                "Stroke", 
                "Cerebral Infarction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients with lower limb spasticity after stroke\n\n          -  duration more than 6 months\n\n          -  Modified Ashworth Scale of ankle joint more than 2\n\n        Exclusion Criteria:\n\n          -  patients with previous botulinum toxin injections to lower limbs\n\n          -  patients with serious hepatic, renal or cardiac dysfunction\n\n          -  patients with respiratory failure\n\n          -  patients who cannot understand the instructions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "79 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01910363", 
            "org_study_id": "A1A2BONT", 
            "secondary_id": "TU001"
        }, 
        "intervention": [
            {
                "arm_group_label": "A2NTX", 
                "description": "Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.", 
                "intervention_name": "A2NTX", 
                "intervention_type": "Drug", 
                "other_name": "A2NTX:low molecular weight (150kDalton) purified botulinum toxin type A2 preparation"
            }, 
            {
                "arm_group_label": "BOTOX", 
                "description": "Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.", 
                "intervention_name": "BOTOX", 
                "intervention_type": "Drug", 
                "other_name": "BOTOX\u00ae:onabotulinumtoxinA (Allergan Co Ltd), commercially available botulinum toxin type A1"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "poststroke spasticity", 
            "lower limb", 
            "botulinum toxin", 
            "A2"
        ], 
        "lastchanged_date": "January 9, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tokushima", 
                    "country": "Japan", 
                    "zip": "770-8503"
                }, 
                "name": "Tokushima University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparison of Clinical Efficacy of Botulinum Neurotoxin Type A1 and A2 for Post-Stroke Lower Limb Spasticity: Phase 2/3", 
        "other_outcome": [
            {
                "description": "Time required for a patient to stand up from sitting position in a chair of 50cm height and walk for 3m.\nIf assistance is needed, the same method of assisting the patient is used throughout the study.", 
                "measure": "Walking Speed for 3m", 
                "safety_issue": "No", 
                "time_frame": "30 days after injection"
            }, 
            {
                "description": "Grasping power of both upper limbs will be measure with a standard grasp measure device in kg units. Because injection is made into lower limbs, any decrease of grasp power will be assessed as the measure of unwanted spread of the toxin action.", 
                "measure": "grasp power", 
                "safety_issue": "Yes", 
                "time_frame": "30 days after injection"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Ministry of Health, Labor and Welfare", 
                "Japan: Ministry of Education, Culture, Sports, Science and Technology"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Modified Ashworth Scale is measured at baseline, 30(27-33) days and 60 (56-63) days after injection. Area under curve of Modified Ashworth Scale changes at day 30 and day 60 after injection", 
            "measure": "Change in Modified Ashworth Scale of the ankle joint", 
            "safety_issue": "No", 
            "time_frame": "30-60 days after injection"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01910363"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Tokushima", 
            "investigator_full_name": "Ryuji Kaji", 
            "investigator_title": "Professor and Chairman, Department of Neurology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Change in Functional Independence Measure (FIM)", 
            "safety_issue": "No", 
            "time_frame": "30 days after injection"
        }, 
        "source": "University of Tokushima", 
        "sponsors": {
            "collaborator": {
                "agency": "Ministry of Health, Labour and Welfare, Japan", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Tokushima", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}